Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFirst Affiliated Hospital of Ningbo University
About this trial
The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients.
Participants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg/kg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg/kg/h (calculated as 1-1.5 mg/kg/h in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge
Eligibility criteria
Qualifiers
Age range: 18-80 years old.
Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer
Is willing and capable of providing consent.
Disqualifiers
Palliative surgery without intention of cure.
Extensive comorbidities (ASA IV).
Patients with known or suspected allergy to lidocaine.
Patients who are currently pregnant or breastfeeding.
Trial design
Treatments tested in this trial
- Lidocaine (drug)
Treatment groups
1,400 Participants
are divided into 2 treatment groupsSponsors and collaborators
First Affiliated Hospital of Ningbo University
Lead sponsor
Second Affiliated Hospital of Wenzhou Medical University
Collaborator
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
Collaborator
Ningbo Medical Center Lihuili Hospital
Collaborator
Source ClinicalTrials.gov